Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study
Back to course
Video Transcription
Video Summary
Asset Caption
Gary K. Steinberg, MD, PhD, FAANS
video presentation
Phase I-IIa study
chronic ischemic stroke
mesenchymal stem cells
safety and clinical outcomes
Powered By